NKTR — Nektar Therapeutics
NASDAQ · Healthcare · Biotechnology
$72.00
+$0.25 (+0.35%)
Nektar Therapeutics (NKTR) is a biotechnology company listed on NASDAQ. It is led by Howard W. Robin, based in 455 Mission Bay Boulevard South, San Francisco, CA, United States, 94158, with about 61 employees. Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Latest reported NKTR revenue for 2025-09-30 was $11.8M. Net income was -$128.0M. Revenue was up 5.5% from 2025-06-30 to 2025-09-30. NKTR currently screens at market cap $307.2M.
Use this NKTR page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the NKTR quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the NKTR SEC filings page. Lician reads the product cache first so this HTML stays unique to Nektar Therapeutics even when a live quote feed is slow.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
NKTR Key Statistics
Market Cap
$307.19M
Volume
90,647
Previous Close
$73.69
Day Range
$74.50 – $76.79
EPS
-$0.58
Revenue
$98.43M
Net Income
-$118.96M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+9.2%
Profit Margin
-120.9%
Employees
61
NKTR Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $98.43M | $90.12M | $92.06M | $25.01M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$118.96M | -$276.06M | -$368.20M | -$523.84M |
| EPS (Diluted) | -$0.58 | -$1.45 | -$1.97 | -$790.00 |
Total Assets
$303.85M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$44.25M
Operating Cash Flow
-$175.71M
Free Cash Flow
$0.00
Nektar Therapeutics Company Information
- CEO, President & Director
- Howard W. Robin
- Headquarters
- 455 Mission Bay Boulevard South, San Francisco, CA, United States, 94158
- Website
- www.nektar.com
- Phone
- 415 482 5300
- IPO / Founded
- 1994-05-03
- Sector
- Healthcare
- Industry
- Biotechnology